Novo Nordisk(US:NVO) Globenewswireยท2025-09-20 23:33Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk A/S securities between May 7, 2025, and July 28, 2025, of the September 30, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Novo Nordisk, alleging that the company provided misleading statements about its growth potential while concealing material adverse facts [4] - Investors who purchased securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - The lawsuit claims that Novo Nordisk overstated its potential in the GLP-1 market and the likelihood of patients switching to its branded alternatives, leading to investor damages when the true information was revealed [4] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [3] Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [2][5] - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [6]